Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium

In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18–50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Brickley, Elizabeth B, Connor, Ruth I, Wieland-Alter, Wendy, Weiner, Joshua A, Ackerman, Margaret E, Arita, Minetaro, Gast, Chris, De Coster, Ilse, Van Damme, Pierre, Bandyopadhyay, Ananda S, Wright, Peter F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400418/
https://www.ncbi.nlm.nih.gov/pubmed/33367918
http://dx.doi.org/10.1093/infdis/jiaa783
_version_ 1784772738759524352
author Brickley, Elizabeth B
Connor, Ruth I
Wieland-Alter, Wendy
Weiner, Joshua A
Ackerman, Margaret E
Arita, Minetaro
Gast, Chris
De Coster, Ilse
Van Damme, Pierre
Bandyopadhyay, Ananda S
Wright, Peter F
author_facet Brickley, Elizabeth B
Connor, Ruth I
Wieland-Alter, Wendy
Weiner, Joshua A
Ackerman, Margaret E
Arita, Minetaro
Gast, Chris
De Coster, Ilse
Van Damme, Pierre
Bandyopadhyay, Ananda S
Wright, Peter F
author_sort Brickley, Elizabeth B
collection PubMed
description In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18–50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2–specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively.
format Online
Article
Text
id pubmed-9400418
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94004182022-08-25 Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium Brickley, Elizabeth B Connor, Ruth I Wieland-Alter, Wendy Weiner, Joshua A Ackerman, Margaret E Arita, Minetaro Gast, Chris De Coster, Ilse Van Damme, Pierre Bandyopadhyay, Ananda S Wright, Peter F J Infect Dis Brief Report In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (aged 18–50 years) previously immunized exclusively with inactivated poliovirus vaccine were administered a single dose of 1 of 2 novel type 2 oral poliovirus vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (n = 15); nOPV2-c2: S2/S15domV/CpG40 (n = 15)) and isolated for 28 days in a purpose-built containment facility. Using stool samples collected near days 0, 14, 21, and 28, we evaluated intestinal neutralization and immunoglobulin A responses to the nOPV2s and found that nOPV2-c1 and nOPV2-c2 induced detectable poliovirus type 2–specific intestinal neutralizing responses in 40.0% and 46.7% of participants, respectively. Oxford University Press 2020-12-24 /pmc/articles/PMC9400418/ /pubmed/33367918 http://dx.doi.org/10.1093/infdis/jiaa783 Text en © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Brickley, Elizabeth B
Connor, Ruth I
Wieland-Alter, Wendy
Weiner, Joshua A
Ackerman, Margaret E
Arita, Minetaro
Gast, Chris
De Coster, Ilse
Van Damme, Pierre
Bandyopadhyay, Ananda S
Wright, Peter F
Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium
title Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium
title_full Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium
title_fullStr Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium
title_full_unstemmed Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium
title_short Intestinal Antibody Responses to 2 Novel Live Attenuated Type 2 Oral Poliovirus Vaccines in Healthy Adults in Belgium
title_sort intestinal antibody responses to 2 novel live attenuated type 2 oral poliovirus vaccines in healthy adults in belgium
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400418/
https://www.ncbi.nlm.nih.gov/pubmed/33367918
http://dx.doi.org/10.1093/infdis/jiaa783
work_keys_str_mv AT brickleyelizabethb intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT connorruthi intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT wielandalterwendy intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT weinerjoshuaa intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT ackermanmargarete intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT aritaminetaro intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT gastchris intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT decosterilse intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT vandammepierre intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT bandyopadhyayanandas intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium
AT wrightpeterf intestinalantibodyresponsesto2novelliveattenuatedtype2oralpoliovirusvaccinesinhealthyadultsinbelgium

Ejemplares similares